1. Home
  2. BEAM vs FCF Comparison

BEAM vs FCF Comparison

Compare BEAM & FCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$24.87

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo First Commonwealth Financial Corporation

FCF

First Commonwealth Financial Corporation

HOLD

Current Price

$21.14

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
FCF
Founded
2017
1934
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.2B
IPO Year
2019
1994

Fundamental Metrics

Financial Performance
Metric
BEAM
FCF
Price
$24.87
$21.14
Analyst Decision
Buy
Buy
Analyst Count
12
4
Target Price
$50.75
$19.75
AVG Volume (30 Days)
1.8M
690.3K
Earning Date
05-06-2026
04-28-2026
Dividend Yield
N/A
2.94%
EPS Growth
82.31
5.76
EPS
N/A
0.81
Revenue
$24,000.00
N/A
Revenue This Year
N/A
$16.32
Revenue Next Year
$33.77
$6.25
P/E Ratio
N/A
$26.11
Revenue Growth
33.33
N/A
52 Week Low
$20.23
$15.00
52 Week High
$38.26
$22.34

Technical Indicators

Market Signals
Indicator
BEAM
FCF
Relative Strength Index (RSI) 40.17 48.33
Support Level $21.63 $20.45
Resistance Level $28.87 $21.41
Average True Range (ATR) 1.28 0.33
MACD -0.39 0.01
Stochastic Oscillator 25.71 51.28

Price Performance

Historical Comparison
BEAM
FCF

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About FCF First Commonwealth Financial Corporation

First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.

Share on Social Networks: